PURE Bioscience (OTCMKTS:PURE) and Valneva (NASDAQ:VALN) Head to Head Comparison

PURE Bioscience (OTCMKTS:PURE) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Volatility & Risk

PURE Bioscience has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500.

Profitability

This table compares PURE Bioscience and Valneva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PURE Bioscience	-108.77%	N/A	-356.86%
Valneva	-67.64%	-76.81%	-26.33%

Valuation and Earnings

This table compares PURE Bioscience and Valneva”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PURE Bioscience	$2.20 million	3.49	-$2.40 million	($0.03)	-2.29
Valneva	$174.66 million	3.11	-$130.33 million	($1.58)	-3.99

PURE Bioscience has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than PURE Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for PURE Bioscience and Valneva, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PURE Bioscience	0	0	0	0	0.00
Valneva	2	0	3	0	2.20

Valneva has a consensus price target of $11.98, suggesting a potential upside of 90.08%. Given Valneva’s stronger consensus rating and higher probable upside, analysts plainly believe Valneva is more favorable than PURE Bioscience.

Institutional and Insider Ownership

11.4% of Valneva shares are held by institutional investors. 35.6% of PURE Bioscience shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Valneva beats PURE Bioscience on 8 of the 14 factors compared between the two stocks.

About PURE Bioscience

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.